

Table of Contents

About the Contributors	vii
Table of Chapters	xvii
Acknowledgments	xxxiii
Introduction	xxxv

PART I: PROCESS

Chapter 1 Internal Investigation of Suspected Wrongdoing by Corporate Employees

§ 1:1	Introduction	1-2
§ 1:2	Steps to Take at the Outset of an Investigation.....	1-3
§ 1:2.1	Who Conducts the Investigation—In-House Counsel or Outside Attorneys?	1-3
§ 1:2.2	Defining the Scope of the Investigation	1-4
§ 1:2.3	Doing a Conflicts Check.....	1-5
§ 1:2.4	Expertise of Counsel	1-6
§ 1:3	Investigative Tools	1-7
§ 1:3.1	Document Holds, Collection, and Review	1-7
§ 1:3.2	Recovering Expenses Incurred During Internal Investigations	1-9
§ 1:3.3	Employee Interviews.....	1-10
[A]	Presence of In-House Counsel at the Interview.....	1-10
[B]	Conducting the Interview	1-11
[C]	Separate Counsel for the Employee.....	1-14
§ 1:3.4	Whether to Prepare a Written Report	1-16
§ 1:3.5	Polygraph Testing.....	1-17
§ 1:3.6	Workplace Searches.....	1-18
§ 1:3.7	Workplace Surveillance	1-19
§ 1:3.8	Drug and Alcohol Testing	1-20
§ 1:4	Attorney-Client Privilege and Attorney Work-Product Protection Regarding Internal Investigations	1-21

§ 1:5	Obstruction of Justice	1-23
§ 1:5.1	Obstruction of Justice Statutes	1-24
§ 1:5.2	Liability of Attorneys	1-27
§ 1:5.3	Guidelines for Counsel	1-28
§ 1:6	Subpoenas and Review of Documents Located Overseas	1-29
§ 1:6.1	Obstruction of Justice in International Cases	1-30
§ 1:7	Indemnification and Advancement of Legal Fees	1-31
§ 1:7.1	Mandatory Indemnification	1-31
§ 1:7.2	Permissive Indemnification	1-33
§ 1:7.3	Advancement of Legal Fees and Expenses	1-34
§ 1:7.4	Constitutional Issues	1-35
§ 1:8	Protection for Whistleblowers Against Retaliation	1-37
§ 1:8.1	FCA Anti-Retaliation Protections.....	1-37
§ 1:8.2	Sarbanes-Oxley Whistleblower Protections	1-38
§ 1:8.3	Retaliation Policies.....	1-39
§ 1:8.4	Disciplining Whistleblowers	1-40
§ 1:8.5	Separation/Confidentiality Agreements.....	1-40
§ 1:9	Practitioner’s Checklist for Conducting Internal Investigations	1-42

**Chapter 2 The Attorney-Client Privilege, Work-Product
Protection, and Self-Critical Privilege in Internal
Investigations**

§ 2:1	Introduction	2-2
§ 2:2	The Attorney-Client Privilege.....	2-2
§ 2:2.1	Elements of the Corporate Attorney-Client Privilege	2-3
§ 2:2.2	Applicability to Experts, Attorney Agents, and the Corporation’s Former Employees	2-4
§ 2:2.3	Attorney’s Duty to Assert Privilege.....	2-6
§ 2:2.4	What the Privilege Does Not Cover	2-7
§ 2:2.5	The Crime-Fraud Exception.....	2-8
§ 2:2.6	Authority to Waive the Corporate Attorney-Client Privilege.....	2-11
§ 2:2.7	Effect of Inadvertent Disclosure of Privileged Information on Waiver.....	2-12
§ 2:3	Work-Product Protection	2-16
§ 2:3.1	Work-Product Protection Qualified	2-17
§ 2:3.2	Applicability to Materials from an Internal Investigation	2-18
§ 2:3.3	Materials Protected by the Work-Product Doctrine.....	2-19

Table of Contents

§ 2:3.4 Government Assertions of Work-Product Protection over Investigative Materials 2-19

§ 2:4 The Department of Justice’s Waiver Policy and the Sentencing Guidelines 2-20

§ 2:4.1 Evolution of DOJ Policy on Waiver of Privilege 2-20

§ 2:4.2 The Principles of Federal Prosecution of Business Organizations..... 2-22

§ 2:4.3 The Yates Memo..... 2-26

§ 2:5 Disclosure to the Government and Its Impact on Waiver of the Attorney-Client Privilege and Work-Product Protection 2-30

§ 2:5.1 Attorney-Client Privilege and Selective Waiver..... 2-30

§ 2:5.2 Work-Product Protection and Selective Waiver..... 2-31

§ 2:6 The Common Interest Privilege..... 2-36

§ 2:6.1 Applicability of the Common Interest Privilege 2-37

§ 2:7 Self-Critical Privilege 2-40

§ 2:7.1 Recognition of the Self-Critical Privilege 2-40

§ 2:7.2 Rejection of the Self-Critical Privilege 2-41

§ 2:8 Government Use of “Filter Teams” to Review Privileged Material..... 2-43

§ 2:9 Additional Practical Waiver Problems in Internal Investigations 2-44

§ 2:9.1 Internal Investigations Because of Business Necessities 2-44

§ 2:9.2 Investigation by and for Management..... 2-46

§ 2:9.3 Use of Regularly Employed Auditor..... 2-47

§ 2:9.4 The Pseudo-Hypothetical..... 2-48

§ 2:9.5 Disclosures to Public Relations Consultants..... 2-48

§ 2:10 Practitioner’s Checklist for Obtaining Benefits of Cooperation Without Waiver 2-51

Chapter 3 Responding to Searches and Seizures

§ 3:1 Search Warrants..... 3-2

§ 3:1.1 Generally 3-2

§ 3:1.2 Specifics of a Search Warrant 3-2

§ 3:1.3 Execution of the Warrant 3-6

§ 3:1.4 Effects of Search and Seizure on Corporations 3-6

§ 3:2 Searching and Seizing Electronic Data 3-9

§ 3:2.1 Warrantless Computer Searches and Seizures 3-11

[A] Exigent Circumstances 3-11

[B] Consent..... 3-12

[C] “Plain View” Exception..... 3-13

[D]	Searches at Border Crossings	3-14
[E]	Exceptions Regarding IP Addresses and Cell Phone Locators	3-18
§ 3:2.2	Warrants to Search Computers and Other Electronic Devices.....	3-22
[A]	Computer Searches that Go Beyond the Scope of the Warrant.....	3-24
[B]	Cell Phone Searches.....	3-25
[C]	Time Limits for Government Seizures of Electronic Information.....	3-26
§ 3:2.3	Out-of-District/-Country Warrants	3-27
§ 3:2.4	Data Privacy and Access	3-29
§ 3:3	Searching and Seizing Other Electronic Communications.....	3-30
§ 3:3.1	Wiretapping	3-30
§ 3:3.2	Intercepting Text Messages and Emails.....	3-31
§ 3:3.3	GPS Tracking.....	3-32
§ 3:4	Protecting Privileged Documents During a Search.....	3-34
§ 3:5	Practitioner’s Checklist for Responding to Searches and Seizures	3-39

Chapter 4 Grand Jury Investigations and Multiple Representations of Witnesses

§ 4:1	Overview of the Grand Jury Process.....	4-2
§ 4:1.1	Responding to a Grand Jury Subpoena	4-4
[A]	Litigation Holds.....	4-4
[B]	Insurance Considerations	4-6
[C]	Review of Relevant Documents.....	4-6
[D]	Unduly Broad Subpoenas.....	4-7
[E]	Discoverability of Documents Subject to Protective Orders	4-8
§ 4:1.2	Motions to Quash Grand Jury Subpoenas.....	4-8
§ 4:1.3	Computer Records and Electronic Documents.....	4-10
§ 4:1.4	Subpoena Compliance and Data Privacy Laws.....	4-14
§ 4:1.5	Motions to Dismiss Grand Jury Indictments.....	4-16
§ 4:1.6	Parallel Proceedings.....	4-19
§ 4:2	Ethical Issues in Multiple Representations Before a Grand Jury.....	4-21
§ 4:2.1	Ethical Considerations and Conflicts of Interest	4-22
§ 4:2.2	New York’s Attorney Ethics Rules	4-29
§ 4:2.3	The Prosecutor’s Response	4-31
§ 4:2.4	The Judicial Response.....	4-32
§ 4:3	Practical Considerations When Considering Multiple Representation	4-35

Chapter 5 Advising Witnesses in Light of Perjury Statutes

§ 5:1 Introduction 5-1

 § 5:1.1 Federal Perjury Statutes 5-2

 § 5:1.2 Distinctions Between Sections 1621 and 1623 5-4

 § 5:1.3 False Statements Statute 5-5

§ 5:2 Materiality 5-9

 § 5:2.1 Standard for Materiality 5-10

 § 5:2.2 Literal Truth Defense 5-14

§ 5:3 Perjury Prosecution Absent Prosecution for the
 Underlying Offense 5-18

§ 5:4 Dangers of Crossing the Line 5-21

§ 5:5 Perjury Traps 5-23

§ 5:6 Conclusion 5-24

**Chapter 6 Representing Companies and Individuals in
SEC Investigations and Parallel Proceedings**

§ 6:1 SEC Investigations 6-2

 § 6:1.1 Enforcement Scheme 6-3

 [A] Authority and Powers of the Division of
 Enforcement 6-3

 [B] Civil Suits in Federal Courts Versus
 Administrative Proceedings 6-4

 [C] Criminal Enforcement Through DOJ/Parallel
 Proceedings 6-7

 § 6:1.2 How Investigations Arise/Whistleblower Program 6-7

 [A] Origins of Investigations 6-7

 [B] The Whistleblower Program 6-8

 [C] Retaliation Against Whistleblowers 6-10

 [C][1] Terms of Employment 6-10

 [C][2] Confidentiality Agreements 6-11

 [C][3] Severance Agreements 6-11

 [C][4] Repurchase Agreements 6-12

 [D] Whistleblower Awards 6-13

 § 6:1.3 Responding to Investigative Requests—Initial
 Considerations 6-14

 [A] Initial Contact with the Staff 6-14

 [B] Conducting an Inquiry into the Facts 6-15

 [C] Assessing the Facts and Taking Appropriate Steps 6-17

 § 6:1.4 The Investigative Process 6-18

 [A] Informal Inquiries and Formal Investigations 6-18

 [B] Document Preservation, Collection, Review,
 and Production 6-20

 [C] Staff Interviews and Testimony 6-22

§ 6:1.5	Privilege Issues.....	6-24
[A]	Waiver of Privilege.....	6-25
[B]	Fifth Amendment Privilege.....	6-26
§ 6:1.6	Wells Submission Process	6-28
§ 6:1.7	Cooperation and the Seaboard Factors	6-29
§ 6:1.8	Charges and Remedies	6-34
§ 6:1.9	Settlement	6-40
§ 6:1.10	Recent Enforcement Trends	6-46
[A]	Increased Use of Whistleblowers	6-46
[B]	Crypto and Cybersecurity	6-47
[C]	Gatekeeper Accountability	6-50
[D]	Environmental, Social and Governance (ESG)	6-51
[E]	Increased Use of Data Analytics	6-52
[F]	Individual Accountability.....	6-53
§ 6:2	Parallel Proceedings	6-53
§ 6:2.1	General Strategic Issues and Considerations.....	6-54
§ 6:2.2	Admissibility of Statements Made During Parallel Civil Proceedings	6-55
§ 6:2.3	Wiretapping and Parallel Proceedings.....	6-55

Chapter 7 Corporate Compliance Programs Under the Organizational Sentencing Guidelines

§ 7:1	Introduction	7-1
§ 7:2	An Effective Program to Prevent and Detect Violations of Law	7-4
§ 7:2.1	Practical Considerations	7-4
§ 7:2.2	Requirements for an Effective Compliance and Ethics Program.....	7-5
[A]	Standards and Procedures	7-8
[B]	Top-Level Personnel Responsible.....	7-11
[C]	Exclusion of Individuals Who Present Known Risks.....	7-15
[D]	Communications and Training.....	7-18
[E]	Monitoring and Audits	7-20
[E][1]	Internal Auditing and Monitoring	7-20
[E][2]	Employee Hotlines and the Ombudsman	7-21
[E][3]	Business Ethics Questionnaires.....	7-22
[E][4]	Effectiveness Review.....	7-23
[F]	Incentives and Discipline.....	7-24
[G]	Ongoing Compliance Program Enhancements.....	7-25
[H]	Ongoing Risk Assessments	7-26
[I]	Other Guidance	7-27
§ 7:3	<i>Caremark</i> Liability.....	7-28

Chapter 8 Reserved

Chapter 9 Deferred Prosecution Agreements

§ 9:1	Introduction	9-1
§ 9:2	What Is a DPA?	9-2
§ 9:3	Recent Trends	9-4
§ 9:3.1	Developments in Corporate Cooperation and Individual Prosecution Requirements	9-7
§ 9:3.2	Developments in International Cooperation.....	9-10
§ 9:3.3	Changes and Predictions for the Biden Administration	9-14
§ 9:3.4	Congressional Trends.....	9-15
§ 9:4	The Rise of DPAs	9-16
§ 9:5	DPA or Declination?.....	9-21
§ 9:6	The Terms of the Agreement	9-23
§ 9:7	DOJ Guidance on the Use of Corporate Monitors	9-27
§ 9:8	Judicial Review of DPAs.....	9-30
§ 9:9	SEC’s Use of DPAs and NPAs	9-32
§ 9:10	Antitrust DPAs.....	9-35
§ 9:11	DPAs and State Regulators	9-39
§ 9:12	DPAs in the United Kingdom	9-41
§ 9:13	Practical Considerations in Negotiating Deferred Prosecution Agreements	9-45

**PART II: SELECTED SUBSTANTIVE
WHITE COLLAR CRIMINAL & REGULATORY ISSUES**

**Chapter 10 Representing the Drug or Medical Device
Manufacturer in an Investigation**

§ 10:1	Introduction	10-1
§ 10:2	The Statutory and Regulatory Scheme.....	10-2
§ 10:2.1	The FDCA.....	10-2
§ 10:2.2	The Anti-Kickback Statute.....	10-3
§ 10:2.3	The False Claims Act.....	10-4
§ 10:2.4	The Health Care Fraud Statute.....	10-4
§ 10:2.5	The Foreign Corrupt Practices Act.....	10-5
§ 10:2.6	Other Regulatory Tools	10-5
[A]	Corporate Integrity Agreements.....	10-5
[B]	Exclusion from Federal Healthcare Programs.....	10-6
[C]	Fines.....	10-7

§ 10:3	Recent Developments in Enforcement Actions	10-8
§ 10:3.1	Enforcement Actions Against Pharmaceutical Manufacturers	10-8
§ 10:3.2	Enforcement Actions Against Medical and Diagnostic Testing Device Manufacturers.....	10-21
§ 10:3.3	Individual Accountability.....	10-25
§ 10:3.4	<i>Sorrell, Caronia</i> , and First Amendment Challenges	10-32
§ 10:4	FDA Warning and Untitled Letters to Pharmaceutical Companies Regarding Promotional Materials.....	10-37
§ 10:5	Compliance Strategies	10-42
§ 10:6	Conclusion	10-44

Chapter 11 Government Investigations Under the False Claims Act and Its Qui Tam Provisions

§ 11:1	Introduction	11-2
§ 11:2	The FCA Statute.....	11-4
§ 11:2.1	Liability and Damages Provisions	11-4
§ 11:2.2	Qui Tam Provisions	11-9
[A]	Complaint Filed Under Seal.....	11-10
[B]	Provisions Allowing Relators to Share in Monetary Recovery	11-12
[C]	Authority over Dismissal and Settlement	11-14
§ 11:3	Steps of a Government Investigation.....	11-16
§ 11:3.1	Agency Subpoenas	11-16
§ 11:3.2	Civil Investigative Demands.....	11-17
§ 11:3.3	The Government’s Decision to Intervene.....	11-17
§ 11:4	Elements of FCA Liability.....	11-18
§ 11:4.1	False Claim.....	11-18
§ 11:4.2	Intent.....	11-22
§ 11:4.3	Materiality	11-25
§ 11:4.4	Causation	11-31
§ 11:5	FCA Issues in the Healthcare Area	11-33
§ 11:5.1	Off-Label Marketing.....	11-33
[A]	Generally	11-33
[B]	False Statements and First Amendment Issues	11-34
§ 11:5.2	Anti-Kickback Violations	11-38
§ 11:5.3	Pharmaceutical Pricing Cases	11-41
§ 11:5.4	Concealment of Safety Data and Risk Minimization.....	11-42
§ 11:5.5	Rule 9(b) Issues Involving Providers and Manufacturers	11-46
§ 11:5.6	Causation, Individualized Proof, and Damage Issues Involving Providers and Manufacturers	11-50

Table of Contents

§ 11:6 FCA Issues Regarding Government Contractors..... 11-52

 § 11:6.1 Government Contractor Risks 11-52

 § 11:6.2 Combating Risk and Defending Claims..... 11-57

 § 11:6.3 Confronting Concurrent Proceedings..... 11-61

§ 11:7 Defenses 11-62

 § 11:7.1 Statute of Limitations 11-62

 § 11:7.2 Tax Code Cases..... 11-66

§ 11:8 Special Defenses Against a Qui Tam Relator 11-66

 § 11:8.1 Public Disclosure Bar 11-67

 § 11:8.2 Original Source 11-74

 § 11:8.3 First-to-File Bar..... 11-79

§ 11:9 Protection of Whistleblower..... 11-82

§ 11:10 Other Whistleblower Laws..... 11-88

 § 11:10.1 Tax Whistleblower Law 11-88

 § 11:10.2 Securities Whistleblower Law 11-88

Chapter 12 Representation of Companies in Criminal Antitrust Investigations

§ 12:1 Introduction 12-2

§ 12:2 Elements of a Sherman Act Antitrust Criminal Prosecution..... 12-2

 § 12:2.1 Conspiracy..... 12-4

 § 12:2.2 Criminal Intent 12-5

 § 12:2.3 Interstate Nexus 12-5

 § 12:2.4 Statute of Limitations 12-6

§ 12:3 Department of Justice Policy for Prosecution of Sherman Act Cases..... 12-8

 § 12:3.1 Section 1 Criminal Enforcement..... 12-8

 § 12:3.2 Labor Market Criminal Enforcement 12-9

 § 12:3.3 Section 2 Criminal Enforcement..... 12-12

 § 12:3.4 Emphasis on Individual Responsibility 12-13

 [A] Department of Justice Policies 12-13

 [B] Extradition of Foreign Nationals 12-14

§ 12:4 Criminal Penalties 12-17

 § 12:4.1 Individual Sentences 12-18

 § 12:4.2 Corporate Fines 12-20

 [A] Calculation of Fines 12-20

 [B] Largest Imposed Fines..... 12-25

 § 12:4.3 Major Ongoing Antitrust Investigations 12-26

 [A] Generic Drugs Investigation 12-26

 [B] Broiler Chicken..... 12-27

 [C] Procurement Fraud 12-27

 § 12:4.4 Recent Trials 12-29

§ 12:5	DOJ Corporate Leniency Policy	12-30
§ 12:5.1	Pre-Investigation (“Type A”) Leniency	12-30
§ 12:5.2	Leniency After Investigation Has Begun (“Type B”).....	12-30
§ 12:5.3	2022 Leniency Policy FAQs.....	12-31
§ 12:5.4	Leniency for Corporate Directors, Officers, and Employees.....	12-32
§ 12:5.5	Deferred Prosecution Agreements	12-33
§ 12:5.6	Corporate Monitors	12-34
§ 12:6	Extraterritorial Application of U.S. Antitrust Laws.....	12-35
§ 12:7	State Antitrust Prosecutions	12-39
§ 12:8	Antitrust Compliance Strategies.....	12-42

Chapter 13 Asset Forfeiture and Debarment

§ 13:1	Asset Forfeiture	13-2
§ 13:1.1	The Civil Asset Forfeiture Reform Act of 2000	13-3
§ 13:1.2	Initiation of Civil Judicial Forfeiture	13-4
	[A] Pre-Seizure Warrant “Freezing” of Assets	13-4
	[B] Pre-Forfeiture Seizure of Assets.....	13-5
	[C] Pre-Trial Procedures Under Supplemental Rule G....	13-6
§ 13:1.3	Civil Trial Procedure	13-10
	[A] Initial Burden on the Government.....	13-10
	[B] Innocent Owner Defense	13-11
	[C] Bona Fide Purchaser or Seller for Value	13-12
	[D] Knowledge or Reason to Believe Property Subject to Forfeiture.....	13-14
	[D][1] Willful Blindness	13-15
	[D][2] Knowledge in the Law Firm Fee Context	13-15
	[E] The Department of Justice Policy on Forfeiture of Attorney Fees	13-18
	[E][1] Department of Justice Policy on Federal Adoption	13-20
	[F] Use of Potentially Forfeitable Assets to Retain and Pay Counsel	13-22
	[F][1] Criminal Forfeitures	13-22
	[F][2] Civil Forfeitures	13-23
	[G] Excessive Fines Defense.....	13-24
§ 13:1.4	Civil Judicial Forfeiture of Transferred Traceable Assets.....	13-25
§ 13:1.5	Seizure of Fungible Assets.....	13-26
§ 13:1.6	Awards of Attorney Fees to Prevailing Claimants.....	13-28
§ 13:2	Debarment	13-29
§ 13:2.1	Overview of Suspension and Debarment	13-29
§ 13:2.2	Consequences of Suspension and Debarment.....	13-34

Table of Contents

§ 13:2.3	Term of Suspension or Debarment	13-36
§ 13:2.4	Grounds for Imposing Debarment or Suspension.....	13-37
§ 13:2.5	Factors Informing Agency Discretion to Debar or Suspend.....	13-40
§ 13:2.6	Debarment or Suspension Based on Imputation or Affiliation.....	13-42
[A]	Imputation	13-42
[B]	Affiliation	13-43
§ 13:3	Practical Considerations in Addressing Debarment and Suspension for a Firm	13-45

Chapter 14 Money Laundering and Financial Institutions

§ 14:1	Obligations of Financial Institutions in Combating Money Laundering.....	14-2
§ 14:1.1	Overview: Regulatory Framework	14-2
§ 14:1.2	The Money Laundering Control Act	14-6
[A]	Section 1956(a)(1): Conducting Certain Financial Transactions	14-6
[B]	Section 1956(a)(2): Transporting Funds into or out of the United States.....	14-7
[C]	Section 1956(a)(3): “Sting” Operations	14-8
[D]	Section 1957: Money Transactions in “Criminally Derived Property”.....	14-8
[E]	Penalties for Violations	14-9
§ 14:1.3	The Bank Secrecy Act	14-10
[A]	Financial Institutions Are Required to Implement AML Compliance Programs	14-11
[B]	Financial Institutions Are Required to Implement Adequate Customer Identification Programs.....	14-12
[C]	Financial Institutions Are Required to File Suspicious Activity Reports.....	14-15
[D]	Financial Institutions Are Required to File Currency Transaction Reports.....	14-18
[E]	Joint Statements on BSA/AML Collaboration and Innovation	14-19
[F]	Agency Coordination When Imposing Penalties for Violations	14-20
§ 14:1.4	The Emergence of the New York Department of Financial Services As a Prominent Regulatory Force	14-23

§ 14:1.5	Money Laundering Guidance Regarding Foreign Corruption Proceeds.....	14-24
	[A] Account Opening.....	14-28
	[B] Account Transaction Scrutiny.....	14-30
	[C] Suspicious Activity Reporting	14-31
§ 14:1.6	Special Issues for U.S. Financial Institutions Relating to Foreign Banks Utilizing U.S. Correspondent Accounts.....	14-31
	[A] Money Laundering Risks of Correspondent Accounts.....	14-31
	[B] Payable-Through Accounts	14-34
§ 14:2	Money Laundering Enforcement, Penalties, and Trends.....	14-35
§ 14:2.1	Overview and Recent Developments.....	14-35
§ 14:2.2	Penalties for Failing to Maintain an Adequate AML Program	14-37
	[A] Federal Enforcement Actions Following BSA and AML Violations.....	14-37
	[B] DFS’s Prominent Role in AML Enforcement Efforts Against Foreign Banks	14-41
	[C] Focus on Money Services Businesses	14-46
	[D] Increased Scrutiny of Broker-Dealers	14-49
	[E] Personal Liability for BSA/AML Violations.....	14-53
	[F] Penalties for Structuring to Avoid CTRs	14-57
	[G] The Panama Papers.....	14-58
	[H] Venezuela and Expanding Criminal Charges.....	14-60
§ 14:2.3	Digital Currency, Cannabis and Other Emerging Industries Posing AML Challenges.....	14-62
§ 14:2.4	Money Laundering by Corrupt Foreign Leaders: Kleptocracy Initiative	14-66
§ 14:2.5	Combating Terrorism Financing	14-70
§ 14:2.6	Violations of Export Controls and Economic Sanctions Can Lead to Money Laundering Issues for Financial Institutions.....	14-76

Chapter 15 The Foreign Corrupt Practices Act and Global Anti-Corruption Enforcement

§ 15:1	Introduction	15-1
§ 15:1.1	Enforcement Statistics	15-2
§ 15:1.2	Trends in Enforcement Policies, Priorities, and Practices.....	15-12
	[A] Multi-Jurisdictional Cooperation	15-15
	[B] Collateral Litigation.....	15-18

Table of Contents

§ 15:2 The Foreign Corrupt Practices Act..... 15-19

 § 15:2.1 Who Is Subject to the FCPA? 15-19

 § 15:2.2 Anti-Bribery Provisions 15-21

 § 15:2.3 Penalties for Anti-Bribery Provision Violations..... 15-23

 § 15:2.4 Exceptions and Defenses..... 15-24

 § 15:2.5 Accounting Violations..... 15-28

 § 15:2.6 The Resource Guide..... 15-34

§ 15:3 International Cooperation and Anti-Corruption

 Enforcement 15-37

 § 15:3.1 International Conventions on Bribery..... 15-38

 § 15:3.2 The U.K. Bribery Act of 2010 and U.K.

 Enforcement 15-40

 § 15:3.3 Brazilian Anti-Corruption Laws and

 Enforcement 15-45

Chapter 16 Prosecutions for Violations of U.S. Export Controls and Trade Sanctions

§ 16:1 Introduction 16-2

§ 16:2 Export Controls and Economic Sanctions:

 Regulatory Framework..... 16-3

 § 16:2.1 Office of Foreign Assets Control Regulations 16-3

 [A] U.S. Economic Sanctions: History and

 Statutory Authority..... 16-3

 [B] Types of OFAC Regulations and Prohibitions..... 16-7

 [C] OFAC Jurisdiction: Who Should Comply? 16-13

 [D] OFAC’s Reporting, Procedures and Penalties

 Regulations 16-17

 [E] OFAC Exemptions and Licensing Procedures..... 16-19

 [F] Challenging an OFAC Designation..... 16-22

 § 16:2.2 International Traffic in Arms Regulations..... 16-26

 [A] Overview of ITAR Prohibitions 16-27

 [B] Licensing Process and Exemptions..... 16-28

 [C] Summary of Part 130 Requirements 16-30

 [D] Summary of Section 126.1 Requirements 16-31

 [E] Treatment of Dual Nationals/Third-Country

 Nationals 16-32

 § 16:2.3 Export Administration Regulations 16-33

 [A] Overview of EAR Prohibitions 16-34

 [B] Licensing Process and Exceptions 16-35

 [C] Increased Use of End-User Controls 16-39

 [D] Anti-Boycott Regulations 16-40

 § 16:2.4 Determining Appropriate Jurisdiction..... 16-42

 [A] Sanctions or Export? 16-43

 [B] EAR or ITAR Classification?..... 16-44

WHITE COLLAR ISSUES DESKBOOK

§ 16:3 Enforcement 16-46

 § 16:3.1 OFAC Violations: Penalties and Trends 16-47

 § 16:3.2 ITAR Violations: Penalties and Trends 16-56

 § 16:3.3 EAR Violations: Penalties and Trends 16-60

§ 16:4 Compliance with Export Control Regulations..... 16-65

 § 16:4.1 Corporate Compliance Programs 16-65

 § 16:4.2 “Know Your Customer” 16-68

§ 16:5 Responding to Violations 16-70

 § 16:5.1 Voluntary Disclosure Prior to Commencement
 of a Government Investigation 16-70

 [A] Notification and Documentation
 Requirements..... 16-71

 [B] Penalty Enforcement and Mitigation 16-71

 [C] The Decision to Disclose Voluntarily 16-72

 § 16:5.2 Defending Export Control Violations in a
 Government Investigation 16-74

 § 16:5.3 Due Diligence in Mergers and Acquisitions 16-75

Appendices App.-1

Appendix A Yates Memo App. A-1

Appendix B Principles of Federal Prosecution of
Business Organizations..... App. B-1

Appendix C NYCBA Formal Opinion 2004-02 App. C-1

Appendix D DOJ/SEC FCPA Resource Guide App. D-1

Appendix E The Fraud Section’s FCPA Enforcement
Plan and Guidance App. E-1

Appendix F Guidance on Enhanced Security for
Transactions That May Involve Proceeds
of Foreign Official Corruption..... App. F-1

Appendix G Sentencing Guidelines Manual, Chapter 8:
Sentencing of Organizations App. G-1

Appendix H DOJ Corporate Leniency Policy App. H-1

Appendix I DOJ Leniency Policy for Individuals App. I-1

Appendix J SEC Enforcement Manual, Chapter 6:
Cooperation..... App. J-1

Index I-1